Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
MK-677: Evidence Summary
Evidence summary for MK-677 across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to MK-677 overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Growth hormone secretion | Tier B | 6 | Consistently raises GH and IGF-1 levels to youthful ranges in clinical trials |
| Muscle wasting / sarcopenia | Tier C | 3 | Improved lean mass in elderly subjects but mixed functional outcomes |
| Sleep quality | Tier C | 2 | Increased REM and stage IV sleep duration in healthy volunteers |
References (10)
- MK-677 Phase 1: Increased GH and IGF-1. . Journal of Clinical Endocrinology & Metabolism (1995) PMID: 9329386
- MK-677 in GH deficient adults. . Journal of Clinical Endocrinology & Metabolism (1997) PMID: 18981485
- MK-677 in elderly: Increased GH, lean mass. . Annals of Internal Medicine (2001)
- MK-677 in cachexia: Increased appetite and weight. . Journal of Clinical Endocrinology & Metabolism (2008)
- Design, Biological Characterization, and Discovery of Capromorelin Derivatives as Oral Growth Hormone Secretagogue Receptor Type 1a Agonist for the Treatment of Growth Hormone Deficiency. . Journal of medicinal chemistry (2025) PMID: 40091212
- Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines. . Basic & clinical pharmacology & toxicology (2025) PMID: 39668330
- Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. . Nature communications (2021) PMID: 34737341
- LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. . Experimental physiology (2022) PMID: 36303408
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. . Translational andrology and urology (2020) PMID: 32257855
- Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use. . JCEM case reports (2024) PMID: 39145153